Outcomes from treating tuberculosis with rifampicin or rifabutin in HIV-infected persons also receiving antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 68, Issue 5, 2015, Pages e84-e87

  Rawson, Timothy M ^a   Brima, Nataliya ^b   Almajid, Fahad ^c   Pozniak, Anton L ^c   Janmohamed, Azara ^d   Mandalia, Sundhiya ^a,c   Basnayake, Sheena ^c   Kellgren, Lusha ^d   Copas, Andrew J ^b   Miller, Robert F ^b,d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RIFABUTIN; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; DRUG MONITORING; ELECTRONIC MEDICAL RECORD; ENZYME ACTIVITY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT DURATION; TUBERCULOSIS; VIRUS LOAD; ADULT; CLINICAL TRIAL; COMPLICATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; MALE; MULTICENTER STUDY; PROCEDURES; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HUMANS; MALE; RETROSPECTIVE STUDIES; RIFABUTIN; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84925264804     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000515     Document Type: Letter

References (21)

1. Regazzi M, Carvalho AC, Villani P, et al. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins. Clin Pharmacokinet. 2014; 53:489-507.
2. Pozniak AL, Coyne KM, Miller RF, et al. on behalf of the BHIVA Guidelines Subcommittee. British HIV Association guidelines for the treatment of TB/HIV coinfection 2011. HIV Med. 2011;12:517-552.
3. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Available at: http://aidsinfo. nih.gov/contentfiles/adultoi.pdf. Accessed October 22, 2014.
4. Centers for Disease Control and Prevention. Managing drug interactions in the treatment of HIV-related tuberculosis. Available at: http:// www.cdc.gov/tb/publications/guidelines/TB-HIV-Drugs/default.htm Accessed October 24, 2014.
5. Dooley KE, Flexner C, Andrade AS. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. J Infect Dis. 2008;198:948-961.
6. Davies GR, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev. 2007;4:CD005159.
7. Gonzalez Montaner LJ, Natal S, Yonchaiyud P, et al. Rifabutin for the treatment of newly diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Tuber Lung Dis. 1994;75:341-347.
8. McGregor MM, Olliaro P, Womarans L, et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med. 1996;154:1462-1467.
9. Williamson B, Dooley KE, Zhang Y, et al. Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob Agents Chemother. 2013; 57:6366-6369.
10. Gallicano K, Khaliq Y, Carignan G, et al. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 2001;70:149-158.
11. Loeliger A, Suthar AB, Ripin D, et al. Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach? Int J Tuberc Lung Dis. 2012; 16:6-15.
12. Schwander S, Rüsch-Gerdes S, Mateega A, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. Tubercle Lung Dis. 1995;76:210-218.
13. Singh R, Marshall N, Smith CJ, et al. No impact of rifamycin selection on tuberculosis treatment outcome in HIV coinfected patients. AIDS. 2013;23:481-483.
14. Division of AIDS Table for grading the severity of adult and pediatric adverse experiences. National Institute of Allergy and Infectious Diseases. Available at: http://rsc.tech-res.com/ document/safetyandpharmacovigilance/table-for-grading-severity-of-adult-pediatric-adverse-events.pdf. Accessed October 24, 2014.
15. World Health Organization (WHO). Definitions and Reporting Framework for Tuberculosis. Geneva: WHO. Available at: http:// apps.who.int/iris/bitstream/10665/79199/1/9789241505345-eng.pdf. Accessed February 13, 2014.
16. Podlekareva DN, Mocroft A, Post FA, et al. Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. AIDS. 2009;23:367-374.
17. Narita M, Stambaugh J, Hollender E, et al. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis. Clin Infect Dis. 2000; 30:779-783.
18. Nettles RE, Mazo D, Alwood K, et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis. 2004;38: 731-736.
19. Li J, Munsiff SS, Driver CR, et al. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin-or rifabutin-based regimens in New York City, 1997-2000. Clin Infect Dis. 2005;41: 83-91.
20. AIDS Clinical Trials Group: NCT 01601626. A randomized, phase 2b study of a doubledose lopinavir/ritonavir-based antiretroviral regimen with rifampin-based tuberculosis treatment versus a standard-dose lopinavir/ ritonavir-based antiretroviral regimen with rifabutin-based tuberculosis treatment with or without raltegravir in HIV-1-infected persons requiring treatment for active TB and HIV. Available at: https://clinicaltrials.gov/show/ NCT01601626. Accessed October 24, 2014.
21. Lan NT, Thu NT, Barrail-Tran A, et al. Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam. PLoS One. 2014;9:e84866.